Sanofi (NASDAQ:SNY) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note released on Friday.

SNY has been the subject of several other reports. Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a report on Friday, July 26th. Citigroup raised Sanofi to a strong-buy rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $57.50.

Sanofi Trading Down 1.1 %

Sanofi stock opened at $57.63 on Friday. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company’s fifty day moving average price is $54.34 and its two-hundred day moving average price is $50.48. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market capitalization of $145.96 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.95 EPS. On average, analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC lifted its holdings in shares of Sanofi by 1,153.1% during the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD increased its stake in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Finally, Armistice Capital LLC acquired a new position in Sanofi in the fourth quarter worth about $51,520,000. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.